APOB and chronic kidney disease: The present study uses innovative methods to readily isolate LDL, assess its particle size and fractionate its main components (apoB100, phospholipids, triglycerides, free cholesterol, and cholesteryl esters) to identify/quantify in them certain oxidative modifications as potential clinical markers of oxLDL status in atherosclerosis associated CVDs, with indicative application to CKD-5d patients.